These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 26220846

  • 1. A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
    Goji T, Kimura T, Miyamoto H, Takehara M, Kagemoto K, Okada Y, Okazaki J, Takaoka Y, Miyamoto Y, Mitsui Y, Matsumoto S, Sueuchi T, Tanaka K, Fujino Y, Takaoka T, Kitamura S, Okamoto K, Kimura M, Sogabe M, Muguruma N, Okahisa T, Sato Y, Sagawa T, Fujikawa K, Sato Y, Ikushima H, Takayama T.
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):615-20. PubMed ID: 26220846
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
    Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T.
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
    [Abstract] [Full Text] [Related]

  • 3. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, Luo F.
    World J Gastroenterol; 2014 Oct 14; 20(38):13987-92. PubMed ID: 25320537
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
    Sudo K, Hara R, Nakamura K, Kita E, Tsujimoto A, Yamaguchi T.
    Cancer Chemother Pharmacol; 2017 Jul 14; 80(1):195-202. PubMed ID: 28597040
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
    Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, Tawada K, Imagumbai T, Araki H, Sakai M, Hatano K, Kawakami H, Uno T, Ito H, Yokosuka O.
    Int J Radiat Oncol Biol Phys; 2011 May 01; 80(1):119-25. PubMed ID: 20605363
    [Abstract] [Full Text] [Related]

  • 6. A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
    Eguchi H, Nagano H, Kobayashi S, Kawamoto K, Wada H, Hama N, Tomimaru Y, Akita H, Sakai D, Satoh T, Kudo T, Isohashi F, Mori M, Doki Y.
    Cancer Chemother Pharmacol; 2014 Feb 01; 73(2):309-15. PubMed ID: 24258457
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
    Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Toda N, Tada M, Kawabe T, Omata M.
    Oncology; 2009 Feb 01; 77(5):300-3. PubMed ID: 19923869
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
    Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Shirai Y, Nakagawa A, Kawakami H, Uno T, Ito H, Saisho H.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):219-24. PubMed ID: 17189072
    [Abstract] [Full Text] [Related]

  • 15. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H, Morizane C, Sakamoto Y, Kondo S, Ueno H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M, Okusaka T.
    Jpn J Clin Oncol; 2016 Feb 01; 46(2):132-7. PubMed ID: 26685318
    [Abstract] [Full Text] [Related]

  • 16. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
    Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakagawa N, Takahashi S, Ohge H, Sueda T.
    Cancer Chemother Pharmacol; 2017 Apr 01; 79(4):775-781. PubMed ID: 28293715
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y, Sun J, Jiang Z, Zhang L, Liu G.
    J Chemother; 2015 Aug 01; 27(4):227-34. PubMed ID: 25790948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.